Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
KRM Ayurveda IPO
KRM Ayurveda Ltd
₹2,56,000 /1000 sharesMinimum Investment
KRM Ayurveda IPO Details
| Bidding dates | Minimum investment | Lot size | Price range |
|---|---|---|---|
| 19 Jan ‘26 - 21 Jan ‘26 | ₹2,56,000 | 1,000 | ₹128 - ₹135 |
| Issue size | IPO doc | Tentative allotment date | Tentative listing date |
|---|---|---|---|
| 135 Cr | RHP PDF | 22 Jan ‘26 | 27 Jan ‘26 |
| Face value |
|---|
| 10 |
About KRM Ayurveda
Founded in
2019
MD/CEO
Mr Puneet Dhawan
Parent organisation
KRM Ayurveda Ltd
Strengths & Risks of KRM Ayurveda
Strengths
Risks
KRM Ayurveda claims to follow GMP-certified processes and holds an ISO 9001:2015 certification for its quality management system.
KRM Ayurveda claims that its promoter, Dr Puneet Dhawan, has received several recognitions in the Ayurveda and wellness sector. These include the Ayush Young Entrepreneur Award in 2024 and the “Best Ayurveda Doctor in India” title at the International Fame Awards 2023. The company also notes invitations linked to award platforms and recognition events such as TEDx Panoroad in 2024 and the 2025 conference on “Sustainable Healthcare Solutions.”
KRM Ayurveda has reported relatively high employee attrition in recent years, with attrition rates of 31.75 percent in FY25, 78.47 percent in FY24, and 37.04 percent in FY23, based on average employee counts of 359, 432, and 405, respectively. This level of turnover, including among frontline and technical staff, can increase recruitment and training costs, disrupt continuity of service delivery, and lead to loss of institutional knowledge. If the company is unable to attract, train, and retain skilled professionals in critical roles, its operations, customer service quality, and long-term growth plans may be adversely affected.
Delhi accounted for Rs 22.16 crore (28.94 percent) of the company’s revenue in FY25, Rs 30.21 crore (44.98 percent) in FY24, and Rs 51.25 crore (57.40 percent) in FY23. Any adverse political, social, or economic developments, regulatory changes, or operational disruptions in this region could negatively impact the company’s business, results of operations, and financial condition.
The company reported negative cash flow from operations amounting to Rs 0.03 crore in FY25 and Rs 0.89 crore in FY24. This was mainly due to higher cash being tied up in inventories and an increase in trade receivables, while FY24 outflows were mainly due to an increase in other current assets and a decrease in trade payables. Additionally, negative cash flow from investing activities amounted to Rs 4.33 crore in FY25, Rs 0.13 crore in FY24, and Rs 22.94 crore in FY23, on account of the purchase of property, plant, and equipment. If such negative cash flows continue, the company may face constraints on liquidity, impacting its financial condition and ability to support ongoing operations.
The company and its promoter are involved in certain ongoing legal proceedings. The company’s business prospects could be hit in case of adverse judgments in any of these cases.
KRM Ayurveda was incorporated in 2019 and has an operating history of only about six years, which limits the available track record for assessing its business performance and long-term prospects. With relatively few years of financial and operational data, it is hard for investors to evaluate the sustainability of its business model, profitability, and growth trajectory across different market conditions. Any inability of the company to maintain or improve its performance as it scales could adversely affect its business outlook and investor returns.
As of FY25, the company had trade receivables of Rs 12.13 crore, up from Rs 5.53 crore in FY24. Failure to collect these receivables on time or at all can negatively impact the business and its financial condition.
As of FY25, the company had outstanding financial indebtedness of Rs 31.2 crore. Failure to service or repay these loans could harm the company’s operations and financial position.
KRM Ayurveda Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of KRM Ayurveda IPO
| Apply as | Price band | Apply Range | Lot size |
|---|---|---|---|
| Individual investor | ₹128 - 135 | ₹2 - 5 Lakh | 1000 |
For KRM Ayurveda IPO, eligible investors can apply as Individual investor.